Microsoft word - a09777en_a.doc
VersaLyse
REF A09777
100 tests; 100 mL 1 mL / test
VersaLyse Lysing Solution Ready-for-use
Formulation
Number of vials
Volume per test
1 mL (ready-for-use when used with no concomitant fixation)
PRECAUTIONS
PREPARATION OF SAMPLES
This reagent is intended for the lysis of red
1. Do not use the reagent beyond the expiry
The concentration of leucocytes in the sample
blood cells in the preparation of biological
must be less than 104 cells / µL (1010/L). If
samples for flow cytometry analysis. VersaLyse
2. Do not store in the refrigerator, do not
necessary, dilute in PBS to bring the leucocyte
is compatible with all types of cytometers and is
concentration to 5 x 103 / µL (5 x 109/L).
used with or without washing after incubation,
3. Minimize exposure to light during incubation
The erythrocytic concentration in the sample
as long as properly calibrated fluorescent
with fluorescent antibodies.
must be less than 6 x 106/µL (6 x 1012/L), it is
antibodies are used in the protocol. VersaLyse
4. Avoid microbial contamination of the
recommended to dilute sample in PBS in order
also makes it possible to treat samples even
reagents, or false results may occur.
to bring the erythrocytic concentration to
when they have been washed earlier, in order
5. Formaldehyde is toxic and allergenic. It is
to eliminate serum immunoglobulins for
thought to be carcinogenic. Never pipette
If both the leucocytic and erythrocytic
by mouth and avoid all contact with the
concentrations need adjusting, the highest
PRINCIPLE
skin, mucosa, eyes and clothing.
dilution must be used. The procedures use
6. All blood samples must be considered as
100 µL of a non-prediluted or pre-diluted
The sample containing the red blood cells to be
potentially infectious and must be handled
sample per tube.
lysed is exposed to the VersaLyse reagent for
with care (in particular: the wearing of
at least 10 minutes. The major active ingredient
PROCEDURES
protective gloves, gowns and goggles).
of VersaLyse is a cyclic amine which, in contact
NOTE: The procedures below are valid for
7. Blood tubes and disposable material used
with carbonic anhydrase present in red blood
standard applications. Sample and/or
for handling should be disposed of in ad
cells, is transformed into a compound which is
VersaLyse volumes for certain Beckman
hoc containers intended for incineration.
highly lytic for these cells.
Coulter applications may be different. If such is
This reagent is used with specific conjugated
the case, follow the instructions on the
antibodies, able to bind to leucocytes due to the
Venous blood or bone marrow samples must be
technical leaflet of the application.
antigenic determinants they express. The
taken using sterile tubes containing an EDTA
A – Procedure without concomitant fixation
specific staining of leucocytes is achieved by
salt as the anticoagulant.
Preparation of the reagent
incubating the sample with the antibody or
NB: Carefully read in the ANTICOAGULANT
No preparation is necessary. Use VersaLyse
antibodies. The red cells are then removed by
section, the conditions under which other
directly from the vial.
lysis and the leucocytes, unaffected by this
anticoagulants can be used.
PROCEDURE
process, are analyzed by flow cytometry.
For each sample analyzed, in addition to the
Preparations must be stored between 2 and
The samples should be kept at room
test tube, one control tube is required in which
8°C and analyzed rapidly using flow cytometry.
temperature (18 – 25°C) and not shaken. The
the isotypic control corresponding to the
In the case of a delay of several hours before
sample should be homogenized by gentle
specific staining selected is added to the cells.
analysis, they may be fixed with PBS containing
agitation prior to taking the test sample.
1. In each test tube add the amount of
0.1 % formaldehyde (see the technical leaflet of
The samples must be analyzed within 24 hours
antibody recommended by the
the IOTest®3 Fixative Solution – Ref. A07800 –
manufacturer in order to stain 5 x 105
to prepare this PBS with 0.1 % formaldehyde).
WASHED SAMPLES
In this case, prior washing is necessary.
If you have to wash the samples before staining
2. In each control tube add the amount of the
The flow cytometer measures light diffusion and
followed by lysis of the red blood cells, it is
isotypic control recommended by the
the fluorescence of cells. It makes possible the
essential to remove all the supernatant after the
manufacturer to stain 5 x 105 leucocytes.
delimitation of the population of interest within
last centrifugation. An excess of washing buffer
3. Add 100 µL of the sample (prediluted or
the electronic window defined on a histogram,
on the cell pellet can reduce the effectiveness
otherwise) to both tubes. Vortex the tubes
which correlates the orthogonal diffusion of light
(Side Scatter or SS) and the diffusion of
4. Incubate following the conditions set out in
narrow-angle light (Forward Scatter or FS).
METHODOLOGY
the technical leaflet for the antibodies
Other histograms combining two of the different
NECESSARY MATERIAL NOT SUPPLIED
parameters available on the cytometer, can be
• Sampling tubes and material necessary for
5. Add 1 mL of VersaLyse and vortex
used as an aid in the gating stage depending
immediately for 1 second.
on the application chosen by the user.
• Automatic pipettes with disposable tips for
6. Incubate at least 10 minutes at room
The fluorescence of the delimited cells is
10, 20, 100 and 1000 µL.
temperature (18 – 25°C), protected from
analyzed in order to distinguish the positively-
• Plastic haemolysis tubes.
stained events from the unstained ones. The
• Calibration beads: Flow-Set™ In the case of a procedure without
results are expressed as a percentage of
Fluorospheres (Ref. 6607007).
washing, the tubes are ready for cytometric
positive events in relation to all the events
acquired by the gating.
• Specific fluorescent antibodies.
• Isotypic controls.
NB: If the preparations need to be washed,
STORAGE AND STABILITY
• Buffer (PBS: 0.01 M sodium phosphate;
do not analyze before performing steps 7
VersaLyse is stored between 18 and 25°C. If a
0.145 M sodium chloride; pH 7.2).
vial of VersaLyse has been kept inadvertantly in
• Fixation reagent: for example IOTest 3
a refrigerator, bring it to room temperature (18 –
7. Centrifuge for 5 minutes at 150 x g at room
Fixative Solution (Ref. A07800).
25°C) and wait at least one hour before use.
With the vial closed, the reagent is stable up to
8. Remove the supernatant by aspiration.
• Automatic agitator (Vortex type).
the expiry date shown on the vial.
9. Resuspend the cell pellet in 3 mL of PBS.
• Flow cytometer.
After opening, the reagent is stable for 90 days.
10. Centrifuge for 5 minutes at 150 x g at room
11. Remove the supernatant by aspiration and
resuspend the cell pellet in:
A09777EN_A 2003-11-21
− 0.5 mL or 1 mL of PBS plus 0.1% of
ACD and heparin give good results with all
formaldehyde if the preparations are
to
procedures except the procedure without
be kept for more than 2 hours and less
concomitant fixation when it is followed by
than 24 hours. (A 0.1% formaldehyde
washing. With these anticoagulants, we
Cytometer n° 2:
PBS can be obtained by diluting 12.5 µL
recommend the procedure with concomitant
of the IOTest 3 Fixative Solution (Ref.
fixation, followed by washing.
A07800) at its 10X concentration in 1 mL
ANALYSIS
The erythrocyte residues can give rise to a
mL of PBS without
diffraction signal of the narrow angle light
formaldehyde, if the preparations are to
LIMITATIONS OF THE TECHNIQUE
("Forward Scatter" or FS) greater than that
be analyzed within 2 hours.
1. Flow cytometry may produce false results
obtained with other commercial lysis reagents.
if the cytometer has not been aligned
OTE: In all cases, keep the preparations at
As a result, the usual adjustment (or fixed by
between 2 and 8°C and protected from light.
perfectly, if fluorescence leaks have not
default) of the ("threshold") discriminator on this
been correctly compensated for and if the
B – Procedure with concomitant fixation
parameter may be too weak for VersaLyse.
regions have not been carefully
Preparation of the reagent
It is therefore advisable to adjust the cytometer
Extemporaneously prepare the "Fix-and-Lyse"
during the first moments of the acquisition of a
2. Accurate and reproducible results will be
mixture by adding 25
µL of
UNDILUTED
typical preparation. In the case of whole lysed
obtained as long as the procedures used
IOTest 3 10X* Fixative Solution (Ref. A07800) to
blood for example, it is advisable first to
are in accordance with the technical
1ml of VersaLyse.
increase progressively the value of the
insert leaflet and compatible with good
Vortex the tubes for 3 to 5 seconds.
discriminator until the leucocyte populations are
laboratory practices.
(*) NB: in the context of the "Fix-and-Lyse"
visible on a histogram of the FS type
versus
3. In the case of a hyperleucocytosis, dilute
mixture, the IOTest 3 Fixative solution (Ref.
SS ; then to carefully adjust the amplification of
the specimen in PBS so as to obtain 5 x
A07800) is used at a forty fold concentrated
the FS and SS signals to obtain a distribution of
109 leucocytes/L.
solution and not as a 10X solution (nominal
the leucocytic populations identical to that of
4. In the case of a polyglobulinaemia, dilute
figures 1, 2 and 3.
the specimen in PBS so as to obtain 5 x
Prepare a sufficient volume of the "Fix-and
PERFORMANCE
1012 red blood cells/L.
Lyse" mixture depending on the number of
5. VersaLyse must be brought to room
samples to be lysed (1 mL of mixture per tube).
PURITY AND LYMPHOCYTIC RECOVERY
temperature (18 – 25°C) before use.
Procedure
Purity and lymphocytic recovery have been
6. Verify the preparations using the naked
For each sample analyzed, in addition to the
evaluated according to the recommendations of
eye to assess the efficacy of lysis. If they
test tube, one control tube is required in which
the CDC (1). The blood of 10 healthy donors
are cloudy or if the light diffraction
the cells are mixed with the isotypic control
sampled in K3EDTA was labeled with a mixture
histograms are unusual, lysis may be
corresponding to the specific staining selected.
of monoclonal antibodies CD45-FITC and
1. In each test tube, add the amount of
CD14-PE. The mean values of the recovery
7. The erythroblasts may be incompletely
antibody recommended by the and purity as well as the range for the different
lysed and appear on a light diffraction
manufacturer to stain 5 x 105 leucocytes.
procedures are given in the following tables:
histogram in the same location as the
2. In each control tube, add the amount of
isotopic control recommended by the
Without washing
8. Acetazolamide, an inhibitor of carbonic
manufacturer to stain 5 x 105 leucocytes.
Without concomitant
With concomitant fixation
fixation
anhydrase can completely inhibit the
3. Add 100 µL of the sample (prediluted or
Recovery
Recovery
action of VersaLyse.
otherwise) to both tubes. Vortex the tubes
96.4 92.3 96.6 91.6 9. In certain disease states, such as severe
renal failure or haemoglobinopathies,
4. Incubate following the conditions set out in
90.1 / 94.3 95.4 / 98.1 90.1 / 92.6
lysis of red cells may be slow, incomplete
the technical leaflet for the antibodies used.
With washing
or even impossible. In this case, it is
5. Add 1 mL of the "Fix-and-Lyse" mixture and
Without concomitant
With concomitant fixation
recommended to isolate mononucleated
vortex immediately for 1 second.
fixation
cells using a density gradient (Ficoll, for
6. Incubate at least 10 minutes at room
Recovery
Recovery
example) prior to staining.
temperature (18 – 25°C), protected from
95.6 94.0 96.2 97.2
90.3 / 97.3 95.4 / 97.5 92.7 / 99.4
In the case of a procedure without washing,
the tubes are ready for cytometric analysis.
INTRA-LABORATORY REPRODUCIBILITY
See the Appendix for examples and references.
NB: If the preparations need to be washed,
On the same day and on the same cytometer,
do not analyze before performing steps 7 to
31 measurements of the percentage of CD3+
lymphocytes were carried out on the same
TRADEMARKS
The Beckman Coulter logo, COULTER,
7. Centrifuge for 5 minutes at 150 x g at room
sample (whole blood from a healthy donor). The
EPICS, EXPO, Flow-Set, IOTest, System II,
lysis procedure used was concomitant fixation
XL, Cytomics are registered trademarks of
8. Remove the supernatant by aspiration.
in the absence of washing. The results obtained
Beckman Coulter Inc.
9. Resuspend the cell pellet in 3 mL of PBS.
are summarized in the following table:
FACSCalibur is a registered trademark of BD
10. Centrifuge for 5 minutes at 150 x g at room
Biosciences and Company.
11. Remove the supernatant by aspiration and
resuspend the cell pellet in 0.5 mL or 1 mL
MANUFACTURED BY:
of PBS plus 0.1% of formaldehyde if the
preparations are
to be kept for more than 2
INTER-LABORATORY REPRODUCIBILITY
a Beckman Coulter Company
hours and less than 24 hours. (A 0.1%
On the same day and on the same sample
130 avenue de Lattre de Tassigny
formaldehyde PBS can be obtained by
(whole blood from a healthy donor), 31
B.P. 177 – 13276 Marseille Cedex 9
diluting 12.5 µL of the IOTest 3 Fixative
measurements of the percentage of CD3+
Solution (Ref. A07800) at its 10X
lymphocytes were carried out by two
Customer Services: (33) 4 91 17 27 27
concentration in 1 mL of PBS).
technicians and the preparations analyzed
www.beckmancoulter.com
These preparations may be kept 24 hours
using two different cytometers. The lysis
between 2 and 8°C and protected from light.
procedure used was concomitant fixation in the
absence of washing. The results obtained are
The tripotassium salt of EDTA (K
summarized in the following tables:
the best results, irrespective of the methodology
Cytometer n° 1:
used, with or without washing after lysis.
A09777EN_A 2003-11-21
APPENDIX TO REF A09777
EXAMPLES
REFERENCES
The graphs below are biparametric representations (Forward Scatter
1. Nicholson, J.K.A., Hearn, T.L., Cross, G.D., White, M.D., "1997
vs. Side Scatter) of a normal whole blood sample lyzed with VersaLyse
revised guidelines for performing CD4+ T-cell determinations in
(Ref. A09777) using the no fixation concomitant to lysis and no wash
persons infected with human immunodeficiency virus (HIV)", 1997,
MMWR 46, RR-21-29.
2. Ashmore, L.M., Shopp, G.M., Edwards, B.S., "Lymphocyte subset
analysis by flow cytometry. Comparison of three different staining techniques and effects of blood storage", 1989, J. Immunol. Methods, 118, 209-215.
3. Macey, M.G., McCarthy, D.A., Milne, T., Cavenagh, J.D., Newland,
A.C., "Comparative study of five commercial reagents for preparing normal and leukaemic lymphocytes for immunophenotypic analysis by flow cytometry", 1999, Communications Clinical Cytometry, 38, 153-160.
4. Macey, M.G., McCarthy, D.A., van Agthoven, A., Newland, A.C.,
"How should CD34+ cells be analysed? A study of three classes of antibody and five leucocyte preparation procedures", J. Immunol. Methods, 204, 175-188.
5. Vuorte, J., Jansson, S-E., Repo, H., "Evaluation of red blood cell
lysing solutions in the study of neutrophil oxidative burst by the DCFH assay", 2001, Cytometry, 43, 290-296.
Figure 1: Acquisition is with a BECKMAN COULTER® CYTOMICS™ FC 500 flow cytometer. Analysis is with CYTOMICS™ RXP Analysis software.
Figure 2: Acquisition and analysis are with a COULTER® EPICS® XL™ flow cytometer equipped with System II™ software. Analysis is with EXPO™ Cytometer software (Ref. 6605434).
Figure 3: Acquisition is with a BD Biosciences FACSCaliburTM flow cytometer. Analysis is with EXPO™ Cytometer software (Ref. 6605434)
A09777EN_A 2003-11-21
Source: http://yuvis.com.ua/sites/default/files/field/download%20files/a09777_versalyse_lysing_solution.pdf
Juna Amagara Ministries International Mission Team Juna Amagara Ministries Post Office Box 2384 Glen El yn, IL 60138 630-248-9472 [email protected] Contents: Short Term Mission Trip Participant Information --------------------------- 3 Travel Insurance Sources ------------------------------------------------------- 3 Timeline for Traveler ------------------------------------------------------------ 6 Quick Guide to Rukiga / Runyankole ------------------------------------------ 7 Documents to be Filled out and Submitted to JAM Prior to Departure Application ------------------------------------------------------------------------ 9 Waiver of Liability --------------------------------------------------------------- 11 Personal Covenant ---------------------------------------------------------------- 12
Pal iative Medicine 2004; 18: 195¡/201 Haloperidol in palliative careJane Vella-Brincat and AD (Sandy) Macleod Nurse Maude Hospice, Christchurch Haloperidol is one of 20 'essential‘ medications in palliative care. Its use is widespread inpalliative care patients. The pharmacology of haloperidol is complex and the extent andseverity of some of its adverse effects, particularly extrapyramidal adverse effects (EPS),may be related to the route of administration. Indications for the use of haloperidol inpalliative care are nausea and vomiting and delirium. Adverse effects include EPS and QTprolongation. Sedation is not a common adverse effect of haloperidol. It is important thatpalliative care practitioners have a comprehensive understanding of the indications, doses,adverse effects and pharmacology of haloperidol. This review is intended to address theseissues. Pal iative Medicine 2004; 18: 195¡/201